EN

MegaPro Biomedical completed capital increase and introduced new strategic partners

MegaPro Biomedical is a start-up company focusing on the development of nano drug dosage forms and has successfully used its nano-cell drug platform to develop new drugs and completed a number of pre-clinical developments. Since 2017, Giant Biomedical has negotiated with China Chemical & Pharmaceutical Co. (1701) for strategic collaboration and in discussion for the use of technology platforms and enhance the value of products. Sinochem is optimistic about the development of Giant Biomedical and the potential of the nano drug dosage form market, and therefore participated in the series D fundraising of MegaPro, becoming an important strategic partner; in addition to investing in the equity of Giant Biomedical, China Chemical & Pharmaceutical Co. has also obtained the authorization of Giant Biomedical's nano-cell technology to promote the development of future products and accelerate the mass production and marketing of listed products.

Dr. Jassy Wang, general manager of MegaPro Biomedical, states that the company's nano-cell technology mainly uses the coating technology of hydrophobic drugs through polymers. Converting hydrophobic drugs to hydrophilic drugs and maintain nanoscale size, the drugs have the advantages of reducing side effects of hydrophobic drug solvents, increasing dosage and slow release. The addition of China Chemical & Pharmaceutical Co. will draw the company's future development items closer to market demand and accelerate the development of more new dosage forms or new applications. It is envisioned that MegaPro will become a leader in the development of nano-drugs.

At present, MPB-1734, the first product of the nanocell technology platform, has completed the company's internal development preparations, and phase I clinical trials are expected to begin in 2020. The other two MegaPro products in the second phase of clinical trials have also made breakthroughs. MPB-1514 is currently the only injection-type iron preparation made of non-sugars on the market.

Trials with 30 subjects have been completed so far; MPB-1523 MRI hepatocellular carcinoma contrast agent has also completed the acceptance of 30 subjects so far, and the aforementioned two clinical trials are expected to be completed in 2020. The development of each item is going smoothly, and the prospects of development are promising.

MPB-1734 new dosage form anticancer drug has passed the US FDA clinical I/IIa IND application

The MPB-1734 new dosage form anticancer drug developed by MegaPro Biomedical has passed the review of the US FDA, and the IND has been approved for clinical phase I/IIa trial. The development of new formulations of MPB-1734 is based on the nano-microcell technology platform of MegaPro Biomedical. After coating the traditional anti-cancer drugs, the drug can be concentrated on the tumor site through the nano dosage form to enhance the efficacy of the drug, and at the same time, the side effects of traditional cancer drugs are reduced. Cell and animal experiments have shown that it has a significant inhibitory effect on drug-resistant malignant tumors. Therefore, the new formulation of MPB-1734 anti-cancer drug is expected to provide better treatment options for cancer patients.

The results of pre-clinical trials of MPB-1734 new dosage form anticancer drug showed that the highest tolerated dose was three times that of the original drug, and the bone marrow function suppression reaction after injection is milder than that of the original drug. While maintaining immunity, it helps patients complete the course of treatment and improve curative effect. The results of pre-clinical trials have shown that MPB-1734, a new formulation of anticancer drug, can effectively inhibit tumor growth and increase the survival days of diseased animals. At the same time, it can present the antigens of tumor cells, so that the immune system of animals can learn and identify malignant tumors; in the animal test group with the immune node inhibitor (PD-1), combined use of low-dose MPB-1734 new dosage forms of anticancer drugs can effectively inhibit and shrink malignant tumors. In the future, it will be jointly developed with immune drugs to exert an effect of synergy.

The phase I/IIa clinical trial of MPB-1734 new dosage form anticancer drug will be carried out in a multi-country and multi-center manner. The patients who are scheduled to receive treatment are suffering from late parenchymal solid tumors. It is expected to that cases are to be accepted in 2021 and clinical trials are to be completed by the end of 2023.

About MegaPro Biomedical

Giant Biomedical is a new drug development company with nano-drugs as its core and nano-particles and nano-microcells as its technology platform. At present, the nanoparticle product MPB-1523 MRI contrast agent-liver cancer has completed the clinical phase II trial. Another MPB-1514 iron deficiency anemia iron supplement is also expected to start a clinical 2b trial in 2021, MPB-1523 is currently in contact with domestic and foreign pharmaceutical companies to discuss the feasibility of authorization; clinical phase III trials are expected to be carried out with authorized partners based on clinical phase II results. Using nano-cell technology to construct an anti-cancer drug platform, the new dosage form of MPB-1734 anti-cancer drug has also completed the IND application for clinical phase I/IIa of the US FDA. MegaPro will launch more product lines with its highly competitive nanotechnology platform, and through international collaboration, to accelerate product development for clinical use. For further company information, please visit http://www.MegaProbio.com

The company passed the approval of the Industrial Bureau of the Ministry of Economic Affairs for the second time as a new biotechnology drug company

Congratulations! The company has been approved as a new biotechnology drug company by the Industrial Bureau of the Ministry of Economic Affairs for the second time